← Back to patent-cliff list
CAS 796848-79-8
1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea
Codes: LENT-015
Application context (from source-drug indications)
Renal cell carcinomaLenvatinib MesilateEndometrial cancerLenvatinib MesilateHepatocellular carcinomaLenvatinib MesilateThyroid cancerLenvatinib Mesilate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Lenvatinib Mesilate | Tier A — Act now | 2028 |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
4-chloro-7-methoxyquinoline-6-carboxamide→4-amino-3-chlorophenol→phenyl carbonochloridate→cyclopropanamine→phenyl (2-chloro-4-hydroxyphenyl)carbamate→1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | N-(2-Chloro-4-hydroxyphenyl)-N'-cyclopropyl-urea Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.